{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:45:07Z","timestamp":1778341507395,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology, Japan","doi-asserted-by":"crossref","award":["26461154"],"award-info":[{"award-number":["26461154"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s10147-017-1142-x","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T12:20:18Z","timestamp":1495801218000},"page":"872-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["High expression of GRP78\/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma"],"prefix":"10.1007","volume":"22","author":[{"given":"Yosuke","family":"Miura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Sunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsunari","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"issue":"36","key":"1142_CR1","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1200\/jco.2011.36.0487","volume":"29","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Petrini I, Rajan A et al (2011) Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 29(36):4820\u20134827. doi: 10.1200\/jco.2011.36.0487","journal-title":"J Clin Oncol"},{"issue":"4","key":"1142_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ijc.11099","volume":"105","author":"EA Engels","year":"2003","unstructured":"Engels EA, Pfeiffer RM (2003) Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105(4):546\u2013551. doi: 10.1002\/ijc.11099","journal-title":"Int J Cancer"},{"issue":"15","key":"1142_CR3","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1200\/jco.2010.32.9607","volume":"29","author":"GL Lemma","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC et al (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29(15):2060\u20132065. doi: 10.1200\/jco.2010.32.9607","journal-title":"J Clin Oncol"},{"issue":"3","key":"1142_CR4","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","volume":"76","author":"K Kondo","year":"2003","unstructured":"Kondo K, Monden Y (2003) Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 76(3):878\u2013884 (discussion 884\u2013875)","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"1142_CR5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","volume":"14","author":"G Giaccone","year":"1996","unstructured":"Giaccone G, Ardizzoni A, Kirkpatrick A et al (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14(3):814\u2013820","journal-title":"J Clin Oncol"},{"issue":"12","key":"1142_CR6","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","volume":"6","author":"T Agatsuma","year":"2011","unstructured":"Agatsuma T, Koizumi T, Kanda S et al (2011) Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 6(12):2130\u20132134. doi: 10.1097\/JTO.0b013e31822e71c0","journal-title":"J Thorac Oncol"},{"issue":"8","key":"1142_CR7","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1158\/0008-5472.can-07-0325","volume":"67","author":"AS Lee","year":"2007","unstructured":"Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67(8):3496\u20133499. doi: 10.1158\/0008-5472.can-07-0325","journal-title":"Cancer Res"},{"issue":"12","key":"1142_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/nrc1505","volume":"4","author":"Y Ma","year":"2004","unstructured":"Ma Y, Hendershot LM (2004) The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4(12):966\u2013977. doi: 10.1038\/nrc1505","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1142_CR9","first-page":"289","volume":"71","author":"LM Hendershot","year":"2004","unstructured":"Hendershot LM (2004) The ER function BiP is a master regulator of ER function. Mt Sinai J Med 71(5):289\u2013297","journal-title":"Mt Sinai J Med"},{"issue":"7\u20138","key":"1142_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10585-006-9051-9","volume":"23","author":"J Zhang","year":"2006","unstructured":"Zhang J, Jiang Y, Jia Z et al (2006) Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis 23(7\u20138):401\u2013410. doi: 10.1007\/s10585-006-9051-9","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"1142_CR11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/0008-5472.can-07-2950","volume":"68","author":"D Dong","year":"2008","unstructured":"Dong D, Ni M, Li J et al (2008) Critical role of the stress chaperone GRP78\/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 68(2):498\u2013505. doi: 10.1158\/0008-5472.can-07-2950","journal-title":"Cancer Res"},{"issue":"16","key":"1142_CR12","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.1158\/0008-5472.can-06-1660","volume":"66","author":"E Lee","year":"2006","unstructured":"Lee E, Nichols P, Spicer D et al (2006) GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 66(16):7849\u20137853. doi: 10.1158\/0008-5472.can-06-1660","journal-title":"Cancer Res"},{"issue":"10","key":"1142_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.humpath.2007.03.014","volume":"38","author":"S Daneshmand","year":"2007","unstructured":"Daneshmand S, Quek ML, Lin E et al (2007) Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 38(10):1547\u20131552. doi: 10.1016\/j.humpath.2007.03.014","journal-title":"Hum Pathol"},{"issue":"3","key":"1142_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.urology.2009.05.007","volume":"75","author":"W Fu","year":"2010","unstructured":"Fu W, Wu X, Li J et al (2010) Upregulation of GRP78 in renal cell carcinoma and its significance. Urology 75(3):603\u2013607. doi: 10.1016\/j.urology.2009.05.007","journal-title":"Urology"},{"key":"1142_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2407-8-70","volume":"8","author":"R Langer","year":"2008","unstructured":"Langer R, Feith M, Siewert JR et al (2008) Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer 8:70. doi: 10.1186\/1471-2407-8-70","journal-title":"BMC Cancer"},{"issue":"1","key":"1142_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lungcan.2004.12.011","volume":"49","author":"H Uramoto","year":"2005","unstructured":"Uramoto H, Sugio K, Oyama T et al (2005) Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49(1):55\u201362. doi: 10.1016\/j.lungcan.2004.12.011","journal-title":"Lung Cancer"},{"issue":"6","key":"1142_CR17","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ijc.28137","volume":"133","author":"M Thornton","year":"2013","unstructured":"Thornton M, Aslam MA, Tweedle EM et al (2013) The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. Int J Cancer 133(6):1408\u20131418. doi: 10.1002\/ijc.28137","journal-title":"Int J Cancer"},{"issue":"5","key":"1142_CR18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1440-1827.1994.tb02936.x","volume":"44","author":"K Koga","year":"1994","unstructured":"Koga K, Matsuno Y, Noguchi M et al (1994) A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 44(5):359\u2013367","journal-title":"Pathol Int"},{"key":"1142_CR19","unstructured":"Travis W, Brambilla E, Muller-Hermelink H et al (2004) World Health Organization Classification of Tumours: pathology and genetics. Tumours of the lung, pleura, thymus and heart. IARC, Lyon"},{"key":"1142_CR20","doi-asserted-by":"crossref","unstructured":"Miura Y, Kaira K, Sakurai R et al. (2016) Prognostic impact of class III \u03b2-tubulin and topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. Oncol Lett (in press)","DOI":"10.3892\/ol.2017.6419"},{"issue":"3","key":"1142_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ijc.25370","volume":"128","author":"E Lee","year":"2011","unstructured":"Lee E, Nichols P, Groshen S et al (2011) GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer 128(3):726\u2013731. doi: 10.1002\/ijc.25370","journal-title":"Int J Cancer"},{"issue":"4","key":"1142_CR22","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.3892\/ol.2015.3579","volume":"10","author":"R Yerushalmi","year":"2015","unstructured":"Yerushalmi R, Raiter A, Nalbandyan K et al (2015) Cell surface GRP78: a potential marker of good prognosis and response to chemotherapy in breast cancer. Oncol Lett 10(4):2149\u20132155. doi: 10.3892\/ol.2015.3579","journal-title":"Oncol Lett"},{"key":"1142_CR23","doi-asserted-by":"publisher","unstructured":"Wei PL, Kuo LJ, Wang W et al (2012) Silencing of glucose-regulated protein 78 (GRP78) enhances cell migration through the upregulation of vimentin in hepatocellular carcinoma cells. Ann Surg Oncol 19(Suppl 3):S572\u2013S579. doi: 10.1245\/s10434-011-2055-y","DOI":"10.1245\/s10434-011-2055-y"},{"issue":"15","key":"1142_CR24","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1073\/pnas.93.15.7690","volume":"93","author":"C Jamora","year":"1996","unstructured":"Jamora C, Dennert G, Lee AS (1996) Inhibition of tumor progression by suppression of stress protein GRP78\/BiP induction in fibrosarcoma B\/C10ME. Proc Natl Acad Sci USA 93(15):7690\u20137694","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1142_CR25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4161\/cbt.5.7.2970","volume":"5","author":"Y Fu","year":"2006","unstructured":"Fu Y, Lee AS (2006) Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 5(7):741\u2013744","journal-title":"Cancer Biol Ther"},{"issue":"20","key":"1142_CR26","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.can-07-0625","volume":"67","author":"P Pyrko","year":"2007","unstructured":"Pyrko P, Schonthal AH, Hofman FM et al (2007) The unfolded protein response regulator GRP78\/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 67(20):9809\u20139816. doi: 10.1158\/0008-5472.can-07-0625","journal-title":"Cancer Res"},{"issue":"7","key":"1142_CR27","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/ijc.24764","volume":"126","author":"R Tanimoto","year":"2010","unstructured":"Tanimoto R, Sakaguchi M, Abarzua F et al (2010) Down-regulation of BiP\/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC\/Dkk-3. Int J Cancer 126(7):1562\u20131569. doi: 10.1002\/ijc.24764","journal-title":"Int J Cancer"},{"issue":"11","key":"1142_CR28","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1158\/0008-5472.can-04-3426","volume":"65","author":"DJ Davidson","year":"2005","unstructured":"Davidson DJ, Haskell C, Majest S et al (2005) Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 65(11):4663\u20134672. doi: 10.1158\/0008-5472.can-04-3426","journal-title":"Cancer Res"},{"issue":"2","key":"1142_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2009.05.022","volume":"138","author":"R Burikhanov","year":"2009","unstructured":"Burikhanov R, Zhao Y, Goswami A et al (2009) The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138(2):377\u2013388. doi: 10.1016\/j.cell.2009.05.022","journal-title":"Cell"},{"issue":"2","key":"1142_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.canlet.2010.07.016","volume":"332","author":"T Verfaillie","year":"2013","unstructured":"Verfaillie T, Garg AD, Agostinis P (2013) Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett 332(2):249\u2013264. doi: 10.1016\/j.canlet.2010.07.016","journal-title":"Cancer Lett"},{"issue":"10","key":"1142_CR31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/hed.24471","volume":"38","author":"K Kaira","year":"2016","unstructured":"Kaira K, Toyoda M, Shimizu A et al (2016) Decreasing expression of glucose-regulated protein GRP78\/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma. Head Neck 38(10):1539\u20131544. doi: 10.1002\/hed.24471","journal-title":"Head Neck"},{"key":"1142_CR32","doi-asserted-by":"publisher","unstructured":"Kaira K, Toyoda M, Shimizu A et al (2016) Prognostic significance of GRP78\/BiP expression in patients with stage III\/IV hypopharyngeal squamous cell carcinoma. Neoplasma 63(3):477\u2013483. doi: 10.4149\/319_151002n513","DOI":"10.4149\/319_151002n513"},{"issue":"5","key":"1142_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1158\/1535-7163.mct-15-0774","volume":"15","author":"JB Gifford","year":"2016","unstructured":"Gifford JB, Huang W, Zeleniak AE et al (2016) Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol Cancer Ther 15(5):1043\u20131052. doi: 10.1158\/1535-7163.mct-15-0774","journal-title":"Mol Cancer Ther"},{"key":"1142_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.013","author":"M Cerezo","year":"2016","unstructured":"Cerezo M, Lehraiki A, Millet A et al (2016) Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance. Cancer Cell. doi: 10.1016\/j.ccell.2016.04.013","journal-title":"Cancer Cell"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1142-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T01:06:43Z","timestamp":1569373603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1142-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1142-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,26]]}}}